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Abstract
Background: We hypothesized that indocyanine green (ICG) fluorescence patterns using Clairvivo OPT in resected
liver specimens could confirm hepatocellular carcinoma (HCC) better than earlier commercial imaging systems. This
preclinical trial evaluated the effectiveness of fluorescence imaging as an intraoperative cancer navigation tool.
Methods: ICG fluorescence images of resected specimens from 190 patients with HCC were classified into two groups
according to whether high fluorescence was seen in the HCC (high cancerous [HC] group) or in the surrounding liver
tissue (high surrounding [HS] group). The HC and HS groups were sub-classified into whole and partial types and
whole and ring types, respectively.
Results: The HC group had significantly higher prevalence of esophageal or gastric varices, and worse liver function
than patients in the HS group. The HC group also had a higher percentage of limited resection cases than did the HS
group. Cirrhotic liver histology was significantly more common in the HC group than in the HS group. Multivariate
analysis revealed that the HC group was a predictive factor for cirrhosis in HCC patients. Among the HC patients, a
higher percentage of well-differentiated HCC cases were seen in the partial-type subgroup than in the whole-type
subgroup (23/48 (48 %) vs. 7/68 (10 %)). In the HS group, the ring-type subgroup had a higher percentage of poorly
differentiated HCC cases than did the whole-type subgroup (6/37 (16 %) vs. 0/37 (0 %)).
Conclusion: Tumor differentiation and fibrosis in the non-cancerous liver parenchyma could affect ICG fluorescence
imaging in HCC. ICG fluorescence imaging may be a good indication for fibrosis stage. In future, we will try to evaluate
fluorescence imaging with ICG for intraoperative cancer navigation in HCC, using a portable near-infrared fluorescence
imaging system.
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Background
Intraoperative fluorescent angiography is performed after
intravenous (i.v.) injection of indocyanine green (ICG) to
assess the patency of coronary artery bypass grafts [1–4].
Mitsuhashi et al. have reported that intraoperative fluores-
cent imaging during hepatobiliary surgery leads to better
understanding of the anatomy of the hepatic arteries, por-
tal vein, and bile ducts [5]. ICG binds to plasma proteins,
and protein-bound ICG emits near-infrared light [6, 7]. In
all the patients in our department, ICG is administered i.v.
prior to surgery to measure the ICG retention rate at
15 min (ICGR15), to estimate the maximum limit of the
hepatic volume to be resected safely [8, 9].
Human bile also contains proteins that bind to ICG
[10], and we have recently reported that ICG fluorescent
cholangiography can detect insufficiently closed bile duct
stumps that cannot be identified by a standard bile leak
test [11]. ICG fluorescence imaging of liver cancer has
been used recently for intraoperative navigation [12]. We
suggest that liver cancer can be identified by fluorescence
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imaging through visualization of the ICG that remains in
the cancerous tissues and/or surrounding liver tissues
after preoperative intravenous injection.
We hypothesized that ICG fluorescence patterns of
resected HCC specimens using the “Clairvivo OPT,”
which is a special-purpose imaging system for ICG, could
detect hepatocellular carcinoma (HCC) better than earlier
commercial imaging systems. The aim of this preclinical
trial was to evaluate and develop the usefulness of fluores-
cence imaging as an intraoperative cancer navigation tool.
Methods
Patients
We retrospectively reviewed 190 patients with HCC who
underwent R0 resection at our institution between January
2008 and December 2012. All patients provided written
informed consent for participation in this study and the
protocol was approved by the Institutional Ethics Review
Board [The Institutional Review Board for Clinical Research
of Kansai Medical University Hirakata Hospital (protocol
identification number: H1303101). University hospital
medical information network (UMIN) (protocol identifica-
tion number: 000013112)].
Clinicopathological variables and surgery
Before surgery, each patient underwent conventional liver
function tests, and measurement of ICGR15. The fluores-
cent source was ICG (Diagnogreen; Daiichi Sankyo, Tokyo,
Japan), which was injected at a dose of 0.5 mg/kg i.v. at 1–8
weeks prior to surgery. Hepatitis screening was done by
measurement of hepatitis B surface antigen and hepatitis C
antibody. The levels of α-fetoprotein and PIVKA-II (protein
induced by vitamin K absence/antagonism-II) were also
measured in all patients. Surgical procedures were classified
according to the Brisbane terminology proposed by
Strasberg et al. [13]. One senior pathologist reviewed each
specimen for histological confirmation of the diagnosis.
ICG fluorescence imaging of the resected specimens and
fluorescent microscopy
The 242 HCC tumors were resected from a total of 190
patients, of whom 151 patients had solitary tumors, 30
patients had two tumors each, and 9 patients had three
or more tumors. For patients with more than two tu-
mors, we selected the tumor with the largest diameter to
analyze by ICG fluorescence imaging.
In surgical specimens, near-infrared fluorescence images
were taken by Clairvivo OPT (Shimadzu, Kyoto, Japan)
using a filter set with excitation of 785 nm and emission of
845 nm. The system consisted of a horizontal sample table,
excitation light sources, charge-coupled device (CCD) cam-
era, camera lens, optical filter and white laser-emitting
diode light sources illuminating the sample from four dif-
ferent angles. For excitation, five continuous-wave diode la-
sers emitting light at a wavelength of 785 nm and power of
0.07 mW/cm2 illuminated the whole object from five polar
angles of 52, 120, 180, 240 and 308°. Each laser illuminated
the object with a width of 40 mm and length of >120 mm.
Fluorescence emission light was detected by a single CCD
camera. An optical filter was placed in front of the CCD
camera to cut the excitation light when the emission light
was measured. The optical filter was a band-pass interfer-
ence filter with a central wavelength of 845 nm and band
width of 55 nm. The CCD sensor had 1024 × 1024 pixels,
and 4 × 4 binning of the pixels provided 256 × 256 data for
one CCD image [14].
Surgical specimens were fixed with formalin, sectioned at
10 mm, and stained with hematoxylin and eosin. Fluores-
cent microscopy was performed using an upright epifluor-
escence microscope (Eclipse 50i; Nikon Instruments,
Tokyo, Japan) with a cooled CCD camera (Retiga EXi;
QImaging, Surrey, BC, Canada), xenon light source (MAX-
302; Asahi Spectra, Tokyo, Japan), and filters (excitation
775 ± 50 nm and emission 810 nm long pass and 845 ±
55 nm band pass; Chroma Technology, Rockingham, VT,
USA). Fluorescent intensity in the paraffin-embedded sur-
gical specimens was quantified in the cancerous and
Fig. 1 Quantification of fluorescence intensity in paraffin-embedded surgical specimens. Ratio is the average of fluorescence intensity at three points in
the cancerous region (ROI 1, 2 and 3)/average in three points in the non-cancerous surrounding liver tissue (ROI 14, 15 and 16). ROI region of interest
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surrounding liver tissues (counts/mm2) (Fig. 1). The ratio
wasanaverageof fluorescent intensity at threepoints in the
cancerous region/average in three points in the non-
cancerous surrounding liver tissue. We analyzed the ratio
initially in 110 patients; their median ratio was 2.5. For all
190 patients, those who showed high fluorescence in the
HCC tissues (the high cancerous [HC] group, n = 116) and
those with high fluorescence in their surrounding liver tis-
sues (high surrounding [HS] group, n = 74), had ratios of
fluorescent intensity in their cancerous/surrounding liver
tissueof≥2.5and<2.5,respectively.
Predictive factors
We performed univariate and multivariate analysis of 13
clinical factors to identify independent variables related to
cirrhosis (stage F4) in liver histology of patients with
HCC. The perioperative factors we investigated were age,
sex, Child–Pugh class, alcohol abuse, etiology, presence or
absence of esophageal and/or gastric varices, liver function
[including ICGR15, albumin, total bilirubin, platelet count,
aspartate aminotransferase (AST), and alanine amino-
transferase (ALT)], and fluorescence imaging. All of the
variables that were significant according to univariate ana-
lysis were examined with a Cox proportional hazards
model to identify variables that had an independent influ-
ence on liver cirrhosis.
Statistical analysis
Continuous variables were presented as the mean ± stand-
ard deviation (SD). Differences between two groups were
assessed by the Mann–Whitney U test for results as the
mean ± SD. Patients were divided into groups based on the
median values of continuous variables (Table 4). Categorical
data were compared with the χ2 test and Fisher’s exact test
where appropriate. Factors that were found to be significant
by univariate analysis were subjected to multivariate logistic
regression analysis to determine their adjusted odds ratios
(ORs). The OR was used to estimate relative risk of liver
cirrhosis. The level of significance was set at P < 0.05. All
statistical analyses were performed with SPSS for Windows
version 11.0J (SPSS, Chicago, IL, USA).
Results
Table 1 summarizes the preoperative characteristics of
the two groups of patients with HCC. Patients in the
HC group had a significantly higher prevalence of
esophageal or gastric varices, and higher ICGR15, total
bilirubin, AST and ALT, and lower platelet count than
patients in the HS group.
Table 2 shows that operating time, blood loss, and
blood transfusion did not differ significantly between the
two groups. The HC group had a higher percentage of
limited resection cases than the HS group had. On
pathological examination, tumor size, differentiation,
microvascular invasion, number of tumors, and tumor
stage did not differ significantly between the two groups.
Cirrhotic liver histology was significantly more common
in the HC group than in the HS group.
Factors affecting liver cirrhosis
Univariate analysis showed that factors associated
with cirrhosis in patients with HCC were male sex
(P = 0.0056), Child–Pugh class B (P = 0.0495), presence
of esophageal and/or gastric varices (P < 0.0001),
ICGR15 ≥14 % (P < 0.0001), albumin <3.9 g/dL
(P = 0.0143), total bilirubin ≥0.7 mg/dl (P < 0.0001),
platelet count <16 × 104/μL (P < 0.0001), AST ≥39 IU/L
(P = 0.0025), and high cancerous fluorescence imaging
(P < 0.0001). Table 3 shows the results obtained by
multivariate analysis of these factors. Esophageal and/or
gastric varices, high cancerous fluorescence imaging,
ICGR15 ≥14 %, and platelet count <1.6 × 104/μL were
identified as independent prognostic indicators of
cirrhosis.
Classification of positive fluorescence in cancerous or
non-cancerous surrounding liver tissue regions
We sub-classified the HC group into those with whole
(Fig. 2a) or partial (Fig. 2b) types, and the HS group into
those with whole (Fig. 2c) or ring types (Fig. 2d) types.
Table 1 Preoperative clinical characteristics in the high
cancerous (HC) and high surrounding (HS) groups
HC group HS group P
n = 116 n = 74
Sex (male/female) 83/33 60/14 0.1377
Age (years) 68.8 ± 9.3 69.6 ± 9.3 0.5603
HBV/HCV/NBC 18/73/25 12/39/23 0.2953
Alcohol abuse (+) 25 (22 %) 14 (19 %) 0.6613
Esophageal and/or gastric
varices (+)
23 (20 %) 1 (1 %) 0.0002
ICGR15 (%) 18.8 ± 10.5 12.8 ± 7.6 <0.0001
Days between injection of
ICG and operation
25.5 ± 14.0 24.7 ± 12.3 0.7147
Platelet count (×104/mL) 14.2 ± 6.2 19.6 ± 9.6 <0.0001
Total bilirubin (mg/dL) 0.83 ± 0.33 0.69 ± 0.23 0.0016
Albumin (g/dL) 3.7 ± 0.5 3.8 ± 0.5 0.5662
Prothrombin time (%) 89 ± 13 91 ± 11 0.2973
AST (U/L) 51 ± 27 37 ± 22 0.0002
ALT (U/L) 49 ± 34 38 ± 33 0.0427
AFP (ng/mL) 4103 ± 17,724 1829 ± 6357 0.3005
PIVKA-II (mAU/mL) 3476 ± 11,448 2761 ± 9618 0.6657
Values in parentheses are percentages. Data represent mean ± SD or number
of patients
AFP α-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, NBC non-
hepatitis B or C virus
The data in bold was statistically significant
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Preoperative characteristics, perioperative parameters
and pathological findings did not differ significantly be-
tween the whole and partial types in the HC group.
However, the partial type had a higher percentage of
well-differentiated HCC cases than the whole type had.
In addition, in the HS group, the ring type had a higher
percentage of poorly differentiated HCC cases than the
whole type had (Table 4).
Fluorescent microscopy
ICG fluorescent imaging confirmed that significant
fluorescence was demonstrated in the cancerous or non-
cancerous surrounding liver regions of the two surgical
specimens (Figs. 3 and 4). In the HC group, ICG fluores-
cence was identified at the canalicular side of the cancer
cell cytoplasm and pseudoglands of HCC (Fig. 3). In the
HS group, most fluorescence was confirmed in the sur-
rounding non-cancerous liver tissues (Fig. 4).
Discussion
We classified surgical specimens into two groups ac-
cording to ICG fluorescence patterns in the cancerous
and non-cancerous surrounding liver parenchyma (HC
and HS groups). The HC group had significantly more
advanced fibrosis in the non-cancerous liver parenchyma
than the HS group had. Multivariate analysis revealed
that fluorescence imaging in the HC group was a prog-
nostic factor for cirrhosis in HCC patients. In the HC
group, the partial type had a higher percentage of well-
differentiated HCC cases than the whole type had. Previ-
ous reports [15, 16] showed that preoperatively injected
ICG did not pool sufficiently in the tumor, as the arterial
supply in well-differentiated HCC was less than in mod-
erately or poorly differentiated HCC.
Recently Ishizawa et al. [17] reported the mechanisms
of ICG accumulation in liver cancer tissues. They dem-
onstrated that preserved portal uptake of ICG in differ-
entiated HCC cells by Na+/taurocholate co-transporting
polypeptide 8 and organic anion-transporting polypep-
tide 8, with concomitant biliary excretion disorders,
causes accumulation of ICG in cancerous tissues after
preoperative i.v. administration. They classified resected
specimens from 170 HCC patients into two patterns:
ICG fluorescence in the cancerous tissues (cancerous-
type fluorescence); and only in the surrounding non-
cancerous liver parenchyma (rim-type fluorescence). The
cancerous-type fluorescence in HCC was associated with
higher cancer cell differentiation as compared with the
rim-type HCC. In the background characteristics of their
patients with HCC, cirrhotic liver histology and pre-
operative ICGR15 in the cancerous-type HCC were
more common [101/240 (42 %) vs. 8/33 (24 %)] and
higher [median (ranges): 13.0 (3.3–46.5) vs. 10.4 (3.3–
29.6)], respectively, than those in the rim-type. However,
Table 2 Intraoperative and postoperative characteristics of the
high cancerous (HC) and high surrounding (HS) groups
HC group HS group P
n = 116 n = 74
Operating time (min) 349 ± 130 364 ± 136 0.423
Operative blood loss (mL) 1046 ± 1031 1021 ± 950 0.8915
Blood transfusion (+) 18 (16 %) 13 (18 %) 0.8247
Operative procedure
Limited resection 69 (59 %) 22 (30 %) <0.0001
Anatomic resection 47 (41 %) 52 (70 %)
No. of patients with complications 16 (14 %) 8 (11 %) 0.5462
Tumor size (cm) 4.2 ± 3.5 5.2 ± 3.8 0.0798
Tumor differentiation
Well 30 (26 %) 16 (22 %) 0.4813
Moderate 81 (70 %) 52 (70 %)
Poor 5 (4 %) 6 (8 %)
Microvascular invasion (+) 78 (67 %) 53 (72 %) 0.5246
Number of tumors
Single 92 (79 %) 59 (80 %) 0.9444
Multiple 24 (21 %) 15 (20 %)
Liver histology (fibrosis stage)
F0 4 (3 %) 12 (16 %) <0.0001
F1 8 (7 %) 36 (49 %)
F2 10 (9 %) 25 (34 %)
F3 36 (31 %) 0
F4 58 (50 %) 1 (1 %)
Tumor stage (TMN)
I or II 58 (50 %) 28 (38 %) 0.1005
III or IV 58 (50 %) 46 (62 %)
Values in parentheses are percentages. Data represent mean ± SD or number
of patients
F fibrosis
The data in bold was statistically significant
Table 3 Predictive factors for liver cirrhosis identified by
multivariate analysis in patients with hepatocellular carcinoma
Variable Odds ratio 95 % CI P
Male sex 0.47 0.17–1.32 0.1523
Child–Pugh class 1.71 0.21–13.92 0.6161
Esophageal and/or gastric varices 4.02 1.11–14.58 0.034
High cancerous in fluorescence
imaging
33.33 4.18–250 0.0009
ICGR15 ≥ 14 % 3.04 1.20–7.66 0.0187
Albumin <3.9 g/dL 1.11 0.44–2.77 0.8272
Total bilirubin ≥0.7 mg/dL 1.63 0.58–4.55 0.3512
Platelet <16 × 104/mL 3.30 1.24–8.77 0.0169
AST ≥39 IU/L 1.33 0.52–3.38 0.5566
CI confidence interval
The data in bold was statistically significant
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the difference was not significant. The number of pa-
tients with Child–Pugh class B or C was greater in
cancerous-type fluorescence HCC than in rim-type [11/
240 (5 %) vs. 0/33 (0 %)]. We also found that the ring
type in the high non-cancerous group had a higher per-
centage of poorly differentiated HCC cases than the
whole type had.
The interval between injection of ICG and day of op-
eration did not differ significantly between our two
groups: the average interval was 25.5 and 24.7 days in
the HC and HS groups, respectively. No studies have
clearly identified the optimal ICG concentration or
interval between ICG injection and surgery for liver tu-
mors. Kaneko et al. [18] reported that ICG was prefer-
entially taken up by human hepatoma tumors (HuH-7
and HepG2) transplanted subcutaneously into nude
mice. The ICG remained in the HuH-7 tumor for a long
time, maintaining a high tumor-to background ratio for at
least 6 days after ICG administration. However, in clinical
situations, the pharmacokinetics regarding retention and
disappearance of ICG in HCC has not been resolved in
detail. It is unclear whether there is any relation between
fluorescence intensity of ICG in the tumor and fibrosis in
the non-cancerous liver parenchyma. It is necessary to de-
termine the optimal concentration of ICG and the interval
between ICG injection and operation for suitable fluores-
cence imaging of the tumor.
Conclusion
Several near-infrared fluorescence imaging devices
that use various doses of ICG for clinical application
have been developed [19]. An advanced device for
Fig. 2 Whole (a) and partial (b) fluorescence patterns in the cancerous region. Whole- (c) and ring (d) fluorescence patterns in the non-cancerous
surrounding liver tissue
Table 4 Pathological tumor characteristics of whole and partial fluorescence patterns in the high cancerous group, and whole and
ring patterns in high surrounding group ICG fluorescence of HCC
High cancerous group Whole type (n = 68) Partial type (n = 48) P
Tumor differentiation 7/59/2 23/22/3 <0.0001
(well/moderate/poor) (10 %/87 %/3 %) (48 %/46 %/6 %)
High surrounding group Whole type (n = 37) Ring type (n = 37)
Tumor differentiation 8/29/0 8/23/6 0.0352
(well/moderate/poor) (22 %/78 %/0) (22 %/62 %/16 %)
Data represent number (percentage) of patients
The data in bold was statistically significant
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Fig. 3 Fluorescent microscopy in two cases with positive fluorescence in the cancerous region. (a and c) Hematoxylin–eosin staining. (b and d)
Fluorescent microscopy. ICG fluorescence was identified at the canalicular side of the cancer cell cytoplasm and pseudoglands of the HCC
Fig. 4 Fluorescent microscopy in two cases with positive fluorescence in the surrounding liver tissue region. (a and c) Hematoxylin–eosin
staining. (b and d) Fluorescent microscopy. Most fluorescence was confirmed in the non-cancerous surrounding liver tissues
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simultaneous capturing of color and near-infrared im-
ages using a laser-emitting diode and color CCD cam-
era is being developed as a surgery support system.
In conclusion, ICG fluorescence imaging for HCC is
effective for measuring tumor differentiation as well as
fibrosis detection in non-cancerous liver parenchyma.
ICG fluorescence imaging may be a good indicator of
the stage of fibrosis. Further detailed analysis by a
higher-resolution apparatus may be useful for fluores-
cence imaging as an intraoperative cancer navigation
tool. In the immediate future, we will try to evaluate the
fluorescence imaging with ICG for intraoperative cancer
navigation in HCC using the near-infrared fluorescence
imaging system for simultaneous capturing of color and
near-infrared images.
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